Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180611 | 0.91 | MAPK14 (0.48) | MAPK14SMN1; SMN2USP2CYP1A2CYP3A4 | |
| SCHEMBL4339530 | 0.89 | MAPK14 (0.53) | MAPK14SMN1; SMN2USP2CYP1A2CYP3A4 | |
| SCHEMBL6179321 | 0.88 | MAPK14 (0.50) | MAPK14SMN1; SMN2USP2CYP1A2CYP3A4 | |
| SCHEMBL4338910 | 0.88 | MAPK14 (0.52) | MAPK14 | |
| SCHEMBL6179804 | 0.86 | MAPK14 (0.63) | MAPK14 | |
| SCHEMBL6178495 | 0.81 | MAPK14 (0.49) | MAPK14SMN1; SMN2USP2CYP1A2CYP3A4 | |
| SCHEMBL6177933 | 0.80 | MAPK14 (0.47) | MAPK14KMT2AMEN1GAA | |
| SCHEMBL6176484 | 0.80 | MAPK14 (0.53) | MAPK14 | |
| SCHEMBL4338046 | 0.80 | MAPK14 (0.65) | MAPK14CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4335571 | 0.79 | NR3C2 (0.46) | MAPK14KMT2AMEN1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | claimed |
| EP-2044957-A1 | TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | claimed |
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-2044957-A1 | TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| EP-1142890-B1 | AMINOPYRAZOLE DERIVATIVES | TEIKOKU HORMONE MFG CO LTD (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-6511997-B1 | For treatment of a disease associated with tumor necrosis factor alpha, interleukin 1, interleukin 6 or cyclooxygenase II; such as irritable bowel disease | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2003-01-28 | — | — | US | disclosed |
| EP-1142890-A1 | AMINOPYRAZOLE DERIVATIVES | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | MAPK6, SLC10A2, MAP3K6 | MAPK14 13/4885SMN1; SMN2 4214/4885USP2 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.